Bladder cancer
Comparative study of two adjuvant treatments Gemcitabine Docetaxel and BCG for Intermediate and HighRisk Non Muscle Invasive Bladder Cancer
Who can joinAsk the trial team
AgeAsk the trial team
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine and surgery or a procedure
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
Superspeciality Hospital Government Medical College JammuJammuDirections ↗
Registry summary (technical)
Intravesical Gemcitabine Docetaxel vs Bacillus Calmette Guerin A comparative study of adjuvant treatment in Intermediate and High Risk Non Muscle Invasive Bladder Cancer
Sponsor: GMC Jammu
CTRI/2026/01/100721 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 14 Sep 2026 · read by us 5 Nov 2026